IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION
Case Number:
2:16-md-02724
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Sarraf Gentile
- Edelson Lechtzin
- Faegre Drinker
- Krantz & Berman
- Fiddler Gonzalez
- White and Williams
- Berman Tabacco
- Lieff Cabraser
- Ahern & Associates
- Anselmi & Carvelli
- DLA Piper
- Harkins Cunningham
- Hangley Aronchick
- Axinn Veltrop
- Cicala Law Firm
- Zelle LLP
- Boies Schiller
- Armstrong Teasdale
- Ballard Spahr
- Patterson Belknap
- Hagens Berman
- Levin Sedran
- Steptoe LLP
- Baker & Hostetler
- Steven Williams Law
- Arnold & Porter
- Motley Rice
- Tostrud Law Group
- Cleary Gottlieb
- Duane Morris
- Gross & Belsky
- Kohn Swift
- Goldman Scarlato
- Dilworth Paxson
- Freedman Boyd
- Buchanan Ingersoll
- Girard Sharp
- Steyer Lowenthal
- Zuckerman Spaeder
- Cera LLP
- Saiber LLC
- Fox Rothschild
- Sperling Kenny
- Rosenn Jenkins
- Grabar Law
- Garwin Gerstein
- Barrack Rodos
- Schneider Wallace
- Hach Rose Schirripa
- Reed Smith
- Andrus Anderson
- DiCello Levitt
- Cuneo Gilbert
- Welsh & Recker
- Obermayer Rebmann
- DeCotiis FitzPatrick
- Pendley Baudin
- Lite DePalma
- Bailey & Glasser
- Competition Law Partners
- McConnell Valdes
- Wolf Haldenstein
- Neal & Harwell
- Safirstein Law
- Stueve Siegel
- Kaplan Fox
- Sills Cummis
- Linklaters LLP
- Harris St. Laurent
- Dugan Law Firm
- Neufeld Scheck
- Spector Roseman
- Clark Hill
- Berger Montague
- McDermott Will & Emery
- Heins Mills
- Langer Grogan
- Berry Law LLC
- Seeger Weiss
- Hunt Ortmann
- Miller Shah LLP
- Robbins Geller
- WilmerHale
- King & Spalding
- Shipman & Goodwin
- Kirkland & Ellis
- Hughes Hubbard
- Ricci Tyrrell
- Schertler Onorato
- Fenwick & West
- McCune Law
- Cole Schotz
- Faruqi & Faruqi
- Shinder Cantor
- Stradley Ronon
- Roberts Law Firm US
- Wiggin & Dana
- Cohen Milstein
- Kasowitz Benson
- Walsh Pizzi
- Boni Zack
- Shapiro Arato
- Lockridge Grindal
- Debevoise & Plimpton
- Lyden Chappell
- Simpson Thacher & Bartlett LLP
- Morrison Foerster
- Segal McCambridge
- Calcaterra Pollack
- Bonsignore Trial Lawyers
- Blank Rome
- Napoli Shkolnik
- Carella Byrne
- Burns Charest
- McCracken Stemerman
- Hausfeld LLP
- Wisner Baum
- Manatt Phelps
- George Feldman
- Bailey Duquette
- Gibson Dunn
- NastLaw
- Dechert LLP
- Francis Mailman
- Baker Botts
- O’Neill & Borges
- Nussbaum Law Group
- Tycko & Zavareei
- O'Melveny & Myers
- Freshfields
- K&L Gates
- Crowell & Moring
- Wexler Boley
- Marks O'Neill
- Bingham McCutchen
- Venable LLP
- Barrett Law Group
- Stevens & Lee
- Earp Cohn
- Williams & Connolly
- Cozen O'Connor
- Gustafson Gluek
- Scott&Scott
- Skadden Arps
- Miller & Chevalier
- Joseph Saveri Law Firm
- Law Offices of Francis O. Scarpulla
- Petrillo Klein
- Larson King
- Kralowec Law
- Furth Salem
- Greenberg Traurig
- Rule Garza
- Barnes & Thornburg
- Haynes Boone
- Lewis Brisbois
- Weil Gotshal
- Pullman & Comley
- Foley & Lardner
- Hogan Lovells
- Radice Law Firm
- Troutman
- Yarborough Law Firm
- Bartlit Beck
- Kelley Drye
- Lowenstein Sandler
- Proskauer Rose
- Morgan Lewis
- Norton Rose
- Tarter Krinsky
- Cotchett Pitre
- Taus Cebulash
- Spiro Harrison
- Paul Weiss
- Polsinelli PC
- Winston & Strawn
- Lowey Dannenberg
- Goodwin Procter
- Wilson Sonsini
- Seward & Kissel
- Whatley Kallas
- Zimmerman Reed
- Zwerling Schachter
- Glancy Prongay
- Constantine Cannon
- Fine Kaplan
- Grant & Eisenhofer
- Labaton Keller
- Saveri & Saveri
- Curtis Mallet-Prevost
- Latham & Watkins
- White & Case
Companies
- Impax Laboratories, Inc.
- Sun Pharmaceutical Industries Ltd.
- Perrigo Co. PLC
- Sandoz International GmbH
- Cencora Inc.
- Walgreens Boots Alliance Inc.
- Novartis AG
- Red Oak Sourcing LLC
- Endo International PLC
- Aurobindo Pharma Ltd.
- The Harvard Drug Group LLC
- Lupin Ltd.
- Amneal Pharmaceuticals Inc.
- Lannett Company, Inc
- Health Care Service Corp.
- Rite Aid Corp.
- Taro Pharmaceutical Industries Ltd.
- Bi-Lo
- The Cigna Group
- Viatris Inc.
- Humana Inc.
- Hi-Tech Pharmacal Co., Inc.
- Molina Healthcare Inc.
- Allergan PLC
- Par Pharmaceutical Cos. Inc.
- Dr. Reddy's Laboratories Ltd.
- Fougera Pharmaceuticals Inc.
- United Food & Commercial Workers International Union
- Bausch Health Cos. Inc.
- Alvogen Group Inc.
- West-Ward Pharmaceutical Corp.
- Cadila Pharmaceuticals Ltd.
- Ascend Laboratories LLC
- Emcure Pharmaceuticals Ltd.
- Akorn Inc.
- Cardinal Health Inc.
- Avet Pharmaceuticals Inc.
- Camber Pharmaceuticals Inc.
- McKesson Corp.
- Pfizer Inc.
- Glenmark Pharmaceuticals Ltd.
- Zydus Pharmaceuticals Inc.
- International Union Of Operating Engineers
- G&W Laboratories Inc.
- Upsher-Smith Laboratories Inc.
- Winn-Dixie Stores, Inc.
- Wockhardt Ltd.
- Wockhardt USA LLC
- Jubilant Cadista
- American Federation of State County & Municipal Employees
- Teva Pharmaceutical Industries Ltd.
Government Agencies
Sectors & Industries:
-
March 27, 2024
NY AG, Others Blast Sandoz Deal 'Tax' On Future Settlements
New York's attorney general was one of three objectors Tuesday to a provision in Sandoz's proposed $265 million settlement with a class of drug wholesalers in Pennsylvania federal court that they say will delay any future generic-drug price-fixing litigation deals by taxing agreements over $119.25 million.
-
March 14, 2024
Drug Wholesalers Want Preliminary OK On $265M Sandoz Deal
A group of direct purchasers of generic drugs has asked a Pennsylvania federal court for approval of a $265 million settlement with Swiss drugmaker Sandoz over allegations of federal antitrust violations.
-
February 29, 2024
Sandoz To Pay $265M To Resolve Claims In Price-Fixing MDL
Swiss generic drug and biosimilar manufacturer Sandoz announced Thursday that two of its subsidiaries have reached a $265 million settlement with the direct purchasers of generic medications to resolve allegations of federal antitrust violations.
-
February 14, 2024
Settlements of 3 Drug Cos. Get Prelim OK In Price-Fixing MDL
A Pennsylvania federal judge granted preliminary approval Wednesday to settlements in which two makers and one distributor of generic drugs agreed to pay a combined $45 million to resolve allegations they colluded to fix the prices of medications, including those used to treat glaucoma, high blood pressure and high cholesterol.
-
February 01, 2024
State-Led Generic Drug Cases Removed From MDL
The Judicial Panel on Multidistrict Litigation has sent a trio of cases from state-level enforcers back to federal court in Connecticut, separating them from the sprawling MDL centralized in Pennsylvania over claims of price fixing in the generic drug industry.
-
January 23, 2024
3 Generic-Drug Cos. Reach Settlements In Price-Fixing MDL
Generic-drug makers Apotex Corp., Heritage Pharmaceuticals Ltd. and Breckenridge Pharmaceutical Inc. have each agreed to shell out a combined $45 million to settle allegations they colluded to fix the prices of many medications, according to a trio of motions filed Tuesday in multidistrict litigation in Pennsylvania federal court.
-
January 17, 2024
Generic-Drug Cos. Say States Are Mum In MDL Discovery
Generic-drug makers steeped in antitrust multidistrict litigation are asking for an order enforcing a months-old deadline for documents that most states have ignored, according to a memorandum filed in Pennsylvania federal court.
-
December 07, 2023
Generics Price-Fixing Cases Should Stay In MDL, Judge Says
The Pennsylvania federal judge overseeing sprawling multidistrict litigation against generic-drug makers on Thursday told the U.S. Judicial Panel on Multidistrict Litigation that she does not recommend transferring state enforcer actions out of the MDL yet, saying there's more the court can do to get the cases ready for trial or to tee up settlement talks.
-
November 02, 2023
States Want Generic Drug Price-Fixing Claims Back In Conn.
State enforcers accusing several generic drugmakers of price-fixing asked the Judicial Panel on Multidistrict Litigation to move their case back to Connecticut federal court, saying legislation signed by President Joe Biden last year spares state enforcers from the MDL process.
-
October 04, 2023
States Back Off Bid To Block Sandoz Spinoff In Antitrust Case
Novartis AG completed the planned spinoff of its Sandoz unit on Wednesday, after state enforcers and others withdrew their bid to block the move over concerns about recovering alleged overcharges from a sprawling conspiracy to fix generic drug prices.